Newer biologic and small-molecule therapies for inflammatory bowel disease
Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …
bowel disease. This review covers newer treatments that reflect our understanding of the …
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis
Background Data are needed to inform the positioning of biologic therapy in the treatment of
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …
Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease
L Peyrin-Biroulet, JC Chapman… - … England Journal of …, 2024 - Mass Medical Soc
Background The efficacy and safety of risankizumab as compared with ustekinumab in
patients with Crohn's disease are unknown. Methods In this phase 3b, multicenter, open …
patients with Crohn's disease are unknown. Methods In this phase 3b, multicenter, open …
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
2. Methods Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom]
selected a panel of 48 experts supported by a team of methodologists and librarians …
selected a panel of 48 experts supported by a team of methodologists and librarians …
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre …
Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …
ECCO guidelines on therapeutics in Crohn's disease: surgical treatment
M Adamina, S Minozzi, J Warusavitarne… - Journal of Crohn's …, 2024 - academic.oup.com
This article is the second in a series of two publications on the European Crohn's and Colitis
Organisation [ECCO] evidence-based consensus on the management of Crohn's disease …
Organisation [ECCO] evidence-based consensus on the management of Crohn's disease …
Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists
Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are
chronic, progressive, immune-mediated diseases of adults and children that have no cure …
chronic, progressive, immune-mediated diseases of adults and children that have no cure …
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta …
B Barberio, DJ Gracie, CJ Black, AC Ford - Gut, 2023 - gut.bmj.com
Objective There are numerous biological therapies and small molecules licensed for luminal
Crohn's disease (CD), but these are often studied in placebo-controlled trials, meaning …
Crohn's disease (CD), but these are often studied in placebo-controlled trials, meaning …
Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive …
A Assa, M Matar, D Turner, E Broide, B Weiss… - Gastroenterology, 2019 - Elsevier
Background & Aims Proactive monitoring of drug trough concentrations and antibodies
against drugs might help determine whether patients are likely to respond to treatment and …
against drugs might help determine whether patients are likely to respond to treatment and …
Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta …
Background & Aims We performed a systematic review and meta-analysis to evaluate the
comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF …
comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF …